Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
Date:5/5/2009

, were $59.6 million, compared with $72.8 million at December 31, 2008. Management currently believes the existing cash and investment securities will provide adequate resources to fund the Company's operations into the first quarter of 2010.

Goals and Objectives

During the remainder of 2009 Poniard expects to:

  • Present progression-free survival data and safety data from two ongoing Phase 2 trials of picoplatin as first-line treatment for metastatic colorectal and castration-resistant prostate cancers (CRPC) at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO); the Company plans to hold an investor event featuring oncology experts at ASCO on Sunday, May 31;
  • Report top-line results from the pivotal Phase 3 SPEAR trial in SCLC in the second half 2009; and
  • Initiate submission of a New Drug Application with the U.S. Food and Drug Administration for picoplatin as a second-line treatment for SCLC, targeting approval and commercialization in 2010.

About Small Cell Lung Cancer

SCLC is the most aggressive form of lung cancer and tends to be widespread by the time of diagnosis. According to the American Cancer Society, in the U.S. in 2008 an estimated 32,000 new cases of SCLC were expected to be diagnosed and 52,000 SCLC patients were treated with therapy (American Cancer Society, Cancer Facts and Figures 2009). Patients with SCLC have few treatment options and a poor prognosis. Effective second-line treatment for SCLC is a major unmet medical need.

About Colorectal Cancer

CRC is the third most common cancer in both American men and women, and the third leading cause of cancer death in the U.S. In 2008, an estimated 148,810 new cases of colon and rectal cancer were expected to be diagnosed in the U.S., with an esti
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Hospira, Inc. (NYSE: HSP ), a ... about the importance of extrapolation in bringing biosimilars to ... European Biosimilars Group conference in London ... of a pivotal white paper titled, "Why extrapolation ... Speaking at the EGA conference, Sumant ...
(Date:4/24/2015)... , April 24, 2015  Blueprint Medicines ... a selective and potent inhibitor of fibroblast growth ... in models of hepatocellular carcinoma (HCC) that are ... candidate, BLU-554 induced complete tumor regression in a ... FGFR4-activating ligand at the highest dose levels. These ...
(Date:4/23/2015)... April 23, 2015  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, today reported net income for ... $1.12 per diluted share.  Net income for the same ... per diluted share, and non-GAAP net income was $82.1 ... sales for the quarter ended March 31, 2015 increased 13.0 ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
... 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, ... upcoming investor conferences in Paris.  Dr. Fernandes will present at ... CET, May 24, at the Hilton Arc de Triomphe.  Dr. ... at 3:00 p.m. CET, May 24, at the Paris Marriott ...
... May 18, 2011 Perrigo Company (Nasdaq: PRGO ... that it has received tentative approval from the U.S. Food ... Levocetirizine Solution, 2.5 mg/5ml, a generic version of UCB,s Xyzal® ... ANDA application for the generic that can entitle it to ...
Cached Medicine Technology:Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 2Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 3
(Date:4/25/2015)... 25, 2015 In the United States ... above needed treatment for an illicit drug ... Abuse and Mental Health Services Administration’s Survey on Drug ... alarming numbers are harrowing stories of men and women ... . David H. Kerr , founder and retired ...
(Date:4/25/2015)... NV (PRWEB) April 25, 2015 The ... is still eliciting the excitement of the public and ... into the months of May and June. From ... held their biannual tradition of "Special Prayers." More than ... had attended previous Special Prayers and have reported intense ...
(Date:4/25/2015)... April 25, 2015 The URO CENTER of ... has been chosen by the New York Academy of Medicine ... medicine in the field of Urology. , Dr. Ferdinand Valentine, ... speciality, Genito-Urinary diseases. He was a man of rare ... of urology. Not only did he devote his life ...
(Date:4/24/2015)... Bird B Gone, the leader in bird control products ... line of bird control solutions to address the growing threat ... Threaten Pacific, Central and Mississippi Farms , According to an ... of highly pathogenic avian flus in the Pacific, Central and ... wild birds enter poultry farms. The USDA urges farmers to ...
(Date:4/24/2015)... 2015 Ryadon is a leading manufacturer ... capabilities and services to complement any custom hardware requirements ... Program will be offered on all heavy duty drawer ... Receive 10% discount - Order 20+: Receive 20% discount ... Slides Products, Furniture ,Drawer ...
Breaking Medicine News(10 mins):Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 2Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 3Health News:Bird B Gone Offers Solutions to Bird Flu Threat to Poultry Farms 4Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... disease through causing inflammation of the arteries. There is mounting evidence ... new study uncovers a link between the mouth and the heart ... Buffalo find that people with gum disease have higher than normal ... enter the circulation via the gums, and then trigger the liver ...
... way of treating tissue at the back of the mouth is ... 30 per cent of women have a problem with snoring - ... in the soft palate - the area of tissue at the ... tonsils, and the base of the tongue. Surgery that makes this ...
... disease also improves the paralysis experienced by stroke survivors.,Levodopa ... and this may help brain cells involved in controlling ... treatment in Parkinson's disease, but a new trial suggests ... ,// ,Researchers at the Bad Aibling Neurological ...
... Researchers at the University of Pittsburgh School of Medicine ... women's concerns about weight is the first treatment to ... for weight-concerned women assumed that the best approach to ... weight gain after they quit smoking. This study, as ...
... influence the risk of oesophagal cancer. ,A family in Liverpool, ... the genetic basis of cancer of the oesophagus. Twenty one ... five generations. The disease affects those who also have a ... researchers are studying 350 members of the extended Liverpool family. ...
... who eat the healthiest diets also eat a lot of ... Index (HEI) is a measure that US nutritionists have developed ... eating pattern rather than intake of specific nutrients. You get ... milk or meat, ten more possible points for dietary limitations ...
Cached Medicine News:Health News:Stop smoking and reduce weight 2
Mounted on a fully adjustable molded,headband with crown strap and comfort,cushions, the sturdy Halogen III Classic is,lightweight, comfortable and durable....
Mounted on a sturdy, molded headband,the Classic has a fully adjustable crown,strap and cushioning that adds to,your comfort....
... ICON DS Strep A is a qualitative ... from throat swabs. The ICON DS Strep A ... especially in rare and low positive colonization samples. ... format. With outstanding performance, ICON DS Strep A ...
... The Inverness Medical Ovulation Test Kits help ... five ovulation predictor sticks to help you predict ... The tests quickly and accurately detect the increase ... which normally occurs 24 to 48 hours before ...
Medicine Products: